Table 2.
Immune outcomes as a result of measles vaccination
| Rochester cohort (n=982) |
San Diego cohort (n=882) |
U.S. cohort (n=1008) |
Total (n=2,872) |
|
|---|---|---|---|---|
|
Neutralizing antibody titera |
||||
| Mean (SD)* | 1,336 (1,316) | 1,444 (2,017) | 1,307 (2,092) | 1,359 (1,835) |
| Q1; Q3 | 435; 1,769 | 394; 1,666 | 346; 1,519 | 394; 1,683 |
| Median | 902 | 844 | 766 | 845 |
|
IFN-γ ELISPOT, SFU / 2×105cellsb |
||||
| Mean (SD)* | 39 (39.1) | 14.9 (18.5) | 21.4 (27.8) | 25.1 (31.4) |
| Q1; Q3 | 8.33; 57.8 | 4; 21 | 7; 28.7 | 6; 32.7 |
| Median | 27 | 9.67 | 14.7 | 15 |
a
Neutralizing antibody titer (mIU/mL), measured by the plaque reduction microneutralization assays (PRMN);
b
IFN-γ ELISPOT spot forming units (SFU), measured per 2 × 105 PBMCs (mean of measles virus-specific response, measured in triplicate wells, minus the mean of unstimulated response, also measured in triplicate wells)
*
Standard Deviation;
Q1, first quartile, Q3, third quartile